Meichen Q. Jiang

Fujian Medical University Union Hospital, 29 Xinquan Road
Fuzhou, 350001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.

The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.

Journal: Cancer

Published: October 17, 2025

Cu-doped dendritic biodegradable nanoplatforms for augmenting cuproptosis and tumor-starvation therapy through mitochondrial metabolic cascade modulation.

Cu-doped dendritic biodegradable nanoplatforms for augmenting cuproptosis and tumor-starvation therapy through mitochondrial metabolic cascade modulation.

Journal: Materials today. Bio

Published: August 10, 2025

Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features.

Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features.

Journal: Diagnostic pathology

Published: August 10, 2024

MAZ-mediated up-regulation of BCKDK reprograms glucose metabolism and promotes growth by regulating glucose-6-phosphate dehydrogenase stability in triple-negative breast cancer.

MAZ-mediated up-regulation of BCKDK reprograms glucose metabolism and promotes growth by regulating glucose-6-phosphate dehydrogenase stability in triple-negative breast cancer.

Journal: Cell death & disease

Published: January 11, 2024

YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway.

YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway.

Journal: Biology direct

Published: December 24, 2023

Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer.

Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer.

Journal: Frontiers in oncology

Published: December 19, 2022

LncRNA-LINC00472 suppresses the malignant progression of non-small cell lung cancer via modulation of the miRNA-1275/Homeobox A2 axis.

LncRNA-LINC00472 suppresses the malignant progression of non-small cell lung cancer via modulation of the miRNA-1275/Homeobox A2 axis.

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Published: June 29, 2022

Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma.

Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma.

Journal: Frontiers in genetics

Published: June 22, 2022

Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.

Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.

Journal: Journal of translational medicine

Published: May 19, 2022

Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma.

Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma.

Journal: Frontiers in immunology

Published: April 13, 2022

YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m6A-dependent manner.

YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m6A-dependent manner.

Journal: Annals of translational medicine

Published: November 30, 2021

CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.

CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.

Journal: Journal of translational medicine

Published: August 26, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026